Novel thrombin and factor Xa inhibitors: Challenges to reversal of their anticoagulation effects

Sean Yates, Ravi Sarode

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations


PURPOSE OF REVIEW: Warfarin has been the sole oral anticoagulant used in the management of thromboembolic disorders for over 60 years. Target-specific oral anticoagulants (TSOAs) have recently emerged as alternatives to warfarin, because they do not require laboratory monitoring. Nevertheless, with the rising use of TSOAs, there is growing concern among clinicians regarding management of bleeding in patients taking them. Unlike warfarin, there is no antidote or reversal agent for TSOAs. This review summarizes recent developments and attempts to provide a systematic approach to patients on TSOAs presenting with bleeding complications. RECENT FINDINGS: Currently, data involving clinical management of TSOAs are limited and primarily based on ex-vivo or animal models using hemostatic agents with uncertain implications in bleeding patients. There is a pressing need for randomized clinical trials evaluating the safety and efficacy of hemostatic agents. SUMMARY: Without evidence-based guidelines for TSOA management, appropriate patient care requires an understanding of TSOA pharmacology, their effect on coagulation tests and, hence, a correct interpretation of test results, as well as a systematic approach to bleeding complications.

Original languageEnglish (US)
Pages (from-to)552-557
Number of pages6
JournalCurrent Opinion in Hematology
Issue number6
StatePublished - Nov 2013
Externally publishedYes


  • apixaban
  • dabigatran
  • oral anticoagulants
  • prothrombin complex concentrate
  • rivaroxaban
  • warfarin

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Novel thrombin and factor Xa inhibitors: Challenges to reversal of their anticoagulation effects'. Together they form a unique fingerprint.

Cite this